Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation

Mare-Bredemeijer, E.L.D. de; Mancham, Shanta; Utomo, Wesley K.; Canck, I. De; Thielen, M Van; Meester, Els de; Rossau, R.; Laan, Luc J. W. van der; Hansen, Bettina E.; Tilanus, Hugo W.; Kazemier, Geert; Janssen, H.L.A.; Metselaar, Herold J.; Kwekkeboom, Jaap

doi:10.1111/tid.12034

Cited by 8 publications

(7 citation statements)

References 56 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned earlier, outcome after LT has improved considerably over the last decades, but patient and graft survival and quality of life could still be improved . Outcome after LT is often compromised as a result of various causes such as inadequate graft selection and consequent primary nonfunction or delayed graft function, recurrence of disease, ischemic cholangiopathy, and life‐long usage of immunosuppressive drugs and its complications .…”

Section: Circulating Micrornas As Noninvasive Biomarkers In Liver Tramentioning

confidence: 99%

The ins and outs of microRNAs as biomarkers in liver disease and transplantation

et al. 2014

View full text Add to dashboard Cite

Summary Ongoing research is being conducted in the field of transplantation to discover novel, noninvasive biomarkers for assessment of graft quality before transplantation and monitoring of graft injury after transplantation. MicroRNAs (miRNAs) are among the most promising in this field. MiRNAs are small noncoding RNAs that function as important regulators of gene expression in response to cellular stress and disease. An advantage that makes miRNAs attractive candidates for biomarker research is their fast release from cells in response to stress and injury, which can occur via different routes. In the context of liver transplantation (LT), noninvasive measurement and stability of extracellular miRNAs in blood, bile, and graft perfusates has been linked to cell‐type specific injury and early graft outcome following LT. Furthermore, specific intrahepatic miRNA expression patterns have been associated with graft survival and recurrent disease, like hepatitis C virus‐related fibrosis and hepatocellular carcinoma. Therefore, miRNAs with strong predictive value and high sensitivity and specificity might be successfully applied to assess hepatic injury and to diagnose (recurrent) liver disease before, during and after LT. In this review, the current features and future prospects of miRNAs as biomarkers in and out of the liver are discussed.

show abstract

Section: Circulating Micrornas As Noninvasive Biomarkers In Liver Tramentioning

confidence: 99%

The ins and outs of microRNAs as biomarkers in liver disease and transplantation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recently, a group from Rotterdam [13] evaluated 50 polymorphisms in 181 liver transplant patients and their corresponding donors with respect to organ rejection and infections in the recipient. They found no correlation between the gene variants and bacterial and/or fungal infections.…”

Section: Introductionmentioning

confidence: 99%

A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients

et al. 2014

View full text Add to dashboard Cite

BackgroundInfections after liver transplantation are the main cause of death in the first year. Recent reports indicate that NOD2 gene mutations increase the risk for inflammatory bowl disease and the severity of graft-versus-host disease in bone marrow transplant patients. Data on polymorphisms in liver transplant patients are sparse. We analyzed 13 single-nucleotide polymorphisms (SNPs) of 13 different gene variants including the SNPs of NOD2 genes from liver recipients. The aim of the study was to evaluate the impact of the SNPs on dialysis-dependent kidney failure, the incidence of infections and patient survival.MethodsDuring a period of 20-months, 231 patients were recruited in this non-interventional, prospective study. Thirteen different SNPs and their impact on the patients’ survival, infection rate, and use of dialysis were assessed.ResultsNOD 2 wildtype genes were protective with respect to the survival of non-alcoholic, cirrhotic transplant patients (3 year survival: 66.8% wildtype vs. 42.6% gene mutation, p = 0.026). This effect was not observed in alcoholic transplant recipients.The incidence of dialysis-dependent kidney failure and infection in the liver transplant patients was not influenced by NOD 2 gene polymorphisms. No effect was noted in the remaining 12 SNPs.Patients with early allograft dysfunction experienced significantly more infections, required dialysis and had significantly worse survival.In contrast, the donor-risk-index had no impact on the infection rate, use of dialysis or survival.ConclusionNOD2 gene variants seem to play a key role in non-alcoholic, liver transplant recipients. However these data should be validated in a larger cohort.

show abstract

“…Four further articles were manually identified from reference lists. After removing of duplicate studies and detailed evaluation of titles and abstracts, 45 articles were fully assessed for eligibility . Eleven studies (Table ) fulfilled the inclusion and exclusion criteria and were finally included in the present study (PRISMA flow chart shown in Figure ).…”

Section: Resultsmentioning

confidence: 99%

Impact of MBL2 gene polymorphisms on the risk of infection in solid organ transplant recipients: A systematic review and meta-analysis

Fernández‐Ruiz

Giménez

Lora³

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

| INTRODUC TI ONLong-term immunosuppression administered to solid organ transplant (SOT) recipients is associated with an increased risk of infectious complications. Current immunosuppressive drugs are mostly aimed at suppressing T cell-mediated adaptive immunity, potentially giving innate immunity a crucial role in protecting against pathogens in the transplant setting. 1,2Mannose-binding lectin (MBL) is a soluble pattern recognition molecule critically involved, along with ficolins, in complement activation through the lectin pathway. 3 This C-type lectin is mainly synthesized in the liver, although extrahepatic sources also exist. By binding to N-acetyl-glucosamine and d-mannose residues on microbial surfaces, MBL activates MBL-associated serine proteases, which cleave complement factors C4 and C2 and induce the formation of

show abstract

Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation

Cited by 8 publications

References 56 publications

The ins and outs of microRNAs as biomarkers in liver disease and transplantation

The ins and outs of microRNAs as biomarkers in liver disease and transplantation

A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients

Impact of MBL2 gene polymorphisms on the risk of infection in solid organ transplant recipients: A systematic review and meta-analysis

Contact Info

Product

Resources

About